Showing 5181-5190 of 7030 results for "".
- Adtralza Pre-Filled Pen Now Available for Canadian Atopic Dermatitis Patientshttps://practicaldermatology.com/news/adtralza-pre-filled-pen-now-available-canadian-atopic-dermatitis-patients/2467019/A new Adtralza® (tralokinumab injection) pre-filled pen has been made available for the first time in Canada for the treatment of moderate-to-severe atopic dermatitis (AD), according to a press announcement from LEO Pharma Inc. The single-use 2 mL pre-filled pen "simplifies the
- More Positive Upadacitinib Data Presentedhttps://practicaldermatology.com/news/more-positive-upadacitinib-data-presented/2467018/New data presented at the Revolutionizing Atopic Dermatitis (RAD) Conference from June 8-10 in Chicago, Illinois, built on previously published top-line results comparing upadacitinib to dupilumab by demonstrating superiority for all ranked secondary endpoints at varying response levels and time
- Roflumilast Cream 0.3% Improves Patient-Reported Outcomes in Psoriasis: Analysishttps://practicaldermatology.com/news/patient-reported-outcomes-improve-roflumilast-cream-03-psoriasis/2466998/A recent study suggested efficacy for roflumilast cream 0.3% for the topical treatment of plaque psoriasis. Researchers for the study pooled data from two Phase 3 clinical trials (DERMIS-1 and DERMIS-2), which included patients aged ≥2 years with plaque psoriasis affecting between 2% and
- FDA Approves First Eyedrops to Treat Mites Living on Eyelasheshttps://practicaldermatology.com/news/fda-approves-first-eyedrops-treat-mites-living-eyelashes/2466993/FDA Approves First Eyedrops to Treat Mites Living on Eyelashes More than 25 million Americans are living with Demodex blepharitis, an underdiagnosed condition that involves mites living on a person’s eyelashes. Demodex blepharitis has gone underdiagnosed for decades because of a l
- Analysis: Deucravacitinib Shows Sustained Efficacy and Safety Over Four Yearshttps://practicaldermatology.com/news/analysis-deucravacitinib-shows-sustained-efficacy-and-safety-over-four-years/2466961/A new analysis suggested that deucravacitinib showed acceptable safety and efficacy over the course of 4 years of treatment. The POETYK PSO-1 and PSO-2 trials, upon which the analysis was based, randomized patients in (1:2:1) to receive placebo, deucravacitinib 6 mg once daily (QD), or a
- Study Highlights Gaps in Dermatology PA Certification Exam Coveragehttps://practicaldermatology.com/news/research-highlights-gaps-dermatology-pa-certification-exam-coverage/2466960/New research suggests that the prevalence of skin disease burden in the United States generally aligns with the physician assistant (PA) certification exam, with areas for improvement. According to the new study published in the Journal of Dermatology Physicians Assistants, the National C
- Rinvoq Now Available for Pediatric Patients with Psoriatic Arthritis and Polyarticular Juvenile Idiopathic Arthritishttps://practicaldermatology.com/news/rinvoq-now-available-pediatric-patients-psoriatic-arthritis-and-polyarticular-juvenile-idiopathic-arthritis/2466955/AbbVie announced that its blockbuster drug Rinvoq (upadacitinib) is now indicated in the US for the treatment of pediatric patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis (pJIA) and psoriatic arthritis (PsA). The medication is indicated for those who had
- Video-assisted Rhino-Septoplasty Technique Shows Validity: Studyhttps://practicaldermatology.com/news/video-assisted-rhino-septoplasty-technique-shows-validity-study/2466916/A new study suggests a video-guided rhino-septoplasty technique showed promise compared with more traditional techniques. "Conservative techniques have been developed in the field of rhinoplasty, focusing on limited tissue resection while emphasizing the reshaping of nasal structural elem
- Study Links Oral Contraceptives and CYP1B1 Variant to Alopecia Riskhttps://practicaldermatology.com/news/study-links-oral-contraceptives-and-cyp1b1-variant-alopecia-risk/2463230/Recent research published in JAMA Dermatology highlighted a potential linkage between the use of oral contraceptive pills (OCP) and the protective effect of a common missense variant in the CYP1B1 gene on the risk of developing frontal fibrosing alopecia (FFA). Researchers for the case-co
- Innovent Plans to Submit NDA in China for Plaque Psoriasis Treatment Picankibart Following Phase 3 Datahttps://practicaldermatology.com/news/innovent-plans-submit-nda-china-plaque-psoriasis-treatment-picankibart-following-phase-3-data/2463195/Innovent Biologics announced that picankibart (IBI112) has met all the primary endpoints and key secondary endpoints in the phase 3 registrational study (CLEAR-1) in Chinese subjects with moderate to severe plaque psoriasis. CLEAR-1 is global the first phase 3 registration study in IL-23p